Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR replacement for subcutaneous Sandostatin in children with diazoxide-resistant congenital hyperinsulinism
2008-003625-16Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide in congenital hyperinsulinism (HI), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Glycemic profile. Started Jun 2008; status: active.
02
Drugs
octreotide
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on 2008-003625-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003625-16.